Siemens Healthcare Diagnostics Products Gmbh

Dade Behring Marburg Gmbh

Behringwerke Aktiengesellschaft

Frank Vitzthum

Stefan Teigelkamp

Harald Althaus

Herbert Schwarz

Juergen Patzke

Tobias Obser

Reinhard Schneppenheim

Hans-Peter Hauser

Bodo Fischer

Norbert F Zander

Thomas Wissel

Gerlinde Christ

Jürgen Patzke

Peter Merle

Thorsten Keller

Matthias Ehm

Roland Barten

Michaela Wicke

G&ouml;tz Walter

Reinhard Prof Schneppenheim

Provided is a universal method for quantitatively determining therapeutic tumor necrosis factor (TNF)-alpha inhibitors in patient samples that is sufficiently sensitive for being able to detect all therapeutic TNF-alpha inhibitors.

Method for quantitatively determining a therapeutic TNF-alpha inhibitor

The present disclosure is in the field of in vitro diagnostics and relates to an easily automatable binding assay for establishing a heparin-induced thrombocytopenia, which binding assay uses Fc&#x3b3;RIIa protein-coated particles.

Binding assay for the diagnosis of a heparin-induced thrombocytopenia

The present invention relates to a functional, easily automatable assay for establishing a heparin-induced thrombocytopenia (HIT). What is measured is the secretion of PF4 (platelet factor 4) from activated thrombocytes.

Activation assay for the diagnosis of a heparin-induced thrombocytopenia

Described herein are method(s), kit(s), reagent(s) and the like for determining von Willebrand factor (VWF) activity in a sample in the absence of ristocetin.

Methods and kits for determining von willebrand factor activity in the absence of ristocetin

Methods and kits for determining von Willebrand factor activity in the absence of ristocetin

The invention relates to binding partners of the placental growth factor (or placenta growth factor, PIGF), especially antibodies directed against the placental growth factor, and production and use thereof.

Binding partners of the placental growth factor, especially antibodies directed against the placental growth factor, and production and use thereof

The invention relates to binding partners of the placental growth factor (or placenta growth factor, PlGF), especially antibodies directed against the placental growth factor, and production and use thereof.

The present invention is in the area of coagulation analysis and relates to antibodies which bind specifically to an immune complex of prothrombin fragment F2/F1+2 and an F2/F1+2 neoepitope-specific antibody fragment, and to the preparation and the use thereof in methods for determining F2/F1+2.

Antibodies for determining the prothrombin fragment F2/F1+2 in a homogeneous immunoassay

Methods and kits for determining von Willebrand factor activity in the absence of ristocetin and for determining the activity of ADAMTS-13 protease

The invention relates to peptides with the Marburg I polymorphism of FSAP and to their preparation and uses, in particular in therapy and diagnosis. The peptides are suitable for use as immunizing antigens for preparing FSAP MR I specific antibodies.

Peptides with the marburg I polymorphism of factor VII-activating protease (FSAP) and their preparation and uses

The invention relates to antibodies which are directed against the FSAP Marburg I variant and to their preparation and use, in particular in therapy and diagnosis. The antibodies are characterized by the fact that they bind specifically to the FSAP MR I variant but not to the FSAP wild-type protein or other mutant variants which are characterized by amino acid substitutions at other positions in the FSAP protein.

Antibodies which are directed against the Marburg I polymorphism of factor VII-activating protease (FSAP), and their preparation and use

The invention relates to human procalcitonin and the preparation and use thereof. In particular, a process for preparing human procalcitonin is described wherein a gene coding for a polypeptide comprising the amino acid sequence of human procalcitonin is inserted into a vector; a host organism is transformed with this gene-containing vector; and the polypeptide expressed by the host organism is isolated. Furthermore the use of the polypeptides according to the invention, in particular as medicaments and diagnostic agents is described.

Human procalcitonin and the preparation and use thereof

The present invention relates to antibodies which, in agueous solution, selectively bind to a transferrin-homologous carbohydrate deficient transferrin (CDT) without the latter needing to be bound to a solid phase. CDT is characterized by at least one of the two oligosaccharide chains which are normally bound to Asn 413 and/or Asn 611 of transferrin being entirely or substantially entirely lacking.

Growing community of inventors

Wetter, Germany

Harald Althaus